RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.

RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.

Benzo[a]pyrene (3,4-Benzopyrene) is classified as “probably carcinogenic to humans” (Group 2A), exhibits lung carcinogenicity in animal models. It is frequently used in chemoprevention studies and two-stage carcinogenesis models.

Pyrithione, a Transition metal complexe, is a zinc ionophore that causes increased zinc levels within mammalian cells. Pyrithione has potent bactericidal and anti-fungal activity.

Cycloleucine is a specific antagonist of NMDA receptor(N-methyl-D-aspartate receptor coupled glycine receptor), with a Ki of 600 μM. Cycloleucine also acts as a specific inhibitor of S-adenosyl-methionine-mediated methylation. Cycloleucine exhibits cytostatic effects.

Cycloleucine is a specific antagonist of NMDA receptor(N-methyl-D-aspartate receptor coupled glycine receptor), with a Ki of 600 μM. Cycloleucine also acts as a specific inhibitor of S-adenosyl-methionine-mediated methylation. Cycloleucine exhibits cytostatic effects.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.